Cytokinetics | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Cytokinetics is a late-stage biopharmaceutical company based in South San Francisco, California, founded in 1997. The organization specializes in discovering, developing, and commercializing muscle activators and inhibitors to treat cardiovascular and neuromuscular diseases impacting muscle function. With decades of research and innovation in muscle biology, it shifted focus exclusively to this domain in 2008.

The company develops small-molecule drug candidates, including first-in-class muscle activators and next-in-class muscle inhibitors. Its pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III trials for heart failure; aficamten, an oral cardiac myosin inhibitor in Phase III trials for hypertrophic cardiomyopathy; and reldesemtiv, a fast skeletal muscle troponin activator in Phase III trials for amyotrophic lateral sclerosis. Cytokinetics collaborates with Ji Xing Pharmaceuticals to develop and commercialize aficamten in Japan, aiming to enhance muscle strength and performance for patients with muscle-related conditions.